Drugs / PHV01
PHV01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06265012 | Feb → Sep 2024 | Marburg hemorrhagic fever | Public Health Vaccines LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PHV01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06265012 ↗ |
| Known as | MARV GP Vaccine | “rVSV∆G-MARV-GP [Angola] (PHV01, MARV GP Vaccine)” NCT06265012 ↗ |
| Known as | rVSV∆G-MARV-GP [Angola] | “rVSV∆G-MARV-GP [Angola] (PHV01, MARV GP Vaccine)” NCT06265012 ↗ |
| Modality | Vaccine | “PHV01 is a live, attenuated rVSV vaccine expressing the MARV GP.” NCT06265012 ↗ |
| Route | Intramuscular | “Participants will receive 1 intramuscular injection of PHV01 or placebo on Day 1 and will be followed for 181 days.” NCT06265012 ↗ |